[Effects of ulinastatin on gut mucosal apoptosis and bacterial translocation in rats with sepsis].
OBJECTIVE
To investigate the effects of ulinastatin on gut mucosal apoptosis and bacterium translocation in a rat model of sepsis.


METHODS
Fifty rats were randomly assigned into 4 groups, namely the control (n=5, no operation or drugs), ulinastatin pretreatment (n=15, treated with 25,000 U/kg ulinastatin 2 h before operation), ulinastatin treatment (n=15, treated with 25,000 U/kg ulinastatin 2 h after operation) and sepsis model (n=15, without drug treatment) groups. The rats in the later 3 groups were subjected to cecal ligation and puncture (CLP). At 3, 6 and 12 h after CLP, the rats were sacrificed and the ileum was removed to examine the pathology and apoptosis of the mucosa. The DNA of Bacillus coli in the whole blood was detected using PCR.


RESULTS
Sepsis caused of epithelial cell loss in the ileal villi, ulceration and blebbing of the lamina propria. Ulinastatin treatment administered before and after the operation both significantly alleviated these morphological anomalies. The sepsis rats showed significantly increased intestinal mucosal apoptotic index as compared with the other 3 groups (P<0.05). Ulinastatin pretreatment, in comparison ulinastatin treatment 12 h after CLP, significantly increased the intestinal mucosal apoptotic index (P<0.05). Bacillus coli DNA was positive in sepsis and postoperative ulinastatin treatment groups but negative in the control and pretreated groups.


CONCLUSIONS
Increased intestinal musocal apoptosis and gut bacterial translocation occur in rats following sepsis, and ulinastatin can effectively decrease intestinal mucosal apoptosis and inhibit bacterial translocation.
Li
Kuang-yi
KY
Department of Emergency, First People's Hospital of Foshan City, Foshan 528000, China.
Jiang
Long-yuan
LY
Zhang
Meng
M
Zhong
Mian
M
Xie
Wen-zuo
WZ
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D018988:Bacterial Translocation / Q000187:drug effects*; D005260:Female; D006023:Glycoproteins / Q000494:pharmacology* / Q000627:therapeutic use; D007082:Ileum / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000188:drug therapy*; D014361:Trypsin Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D006023:Glycoproteins; D014361:Trypsin Inhibitors; C028665:urinastatin